Leila R Zelnick1, Noel S Weiss2, Bryan R Kestenbaum3,2, Cassianne Robinson-Cohen3,2, Patrick J Heagerty4, Katherine Tuttle3,5,6, Yoshio N Hall7, Irl B Hirsch8, Ian H de Boer3,2. 1. Kidney Research Institute, Division of Nephrology, and lzelnick@nephrology.washington.edu. 2. Departments of Epidemiology and. 3. Kidney Research Institute, Division of Nephrology, and. 4. Biostatistics, and. 5. Providence Health Care, Spokane, WA; and. 6. Institute of Translational Health Sciences, University of Washington, Seattle, WA. 7. Department of Medicine, Group Health Cooperative, Seattle, WA. 8. Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine.
Abstract
BACKGROUND AND OBJECTIVES: Diabetes is an important cause of CKD. However, among people with diabetes, it is unclear to what extent CKD is attributable to diabetes itself versus comorbid conditions, such as advanced age and hypertension. We examined associations of diabetes with clinical manifestations of CKD independent of age and BP and the extent to which diabetes contributes to the overall prevalence of CKD in the United States. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a cross-sectional study of 15,675 participants in the National Health and Nutrition Examination Surveys from 2009 to 2014. Diabetes was defined by use of glucose-lowering medications or hemoglobin A1c ≥6.5%. eGFR was calculated using the CKD Epidemiology Collaboration formula, and albumin-to-creatinine ratio was measured in single-void urine samples. We calculated the prevalence of CKD manifestations by diabetes status as well as prevalence ratios, differences in prevalence, and prevalence attributable to diabetes using binomial and linear regression, incorporating data from repeat eGFR and urine albumin-to-creatinine ratio measurements to estimate persistent disease. RESULTS: For participants with diabetes (n=2279) versus those without diabetes (n=13,396), the estimated prevalence of any CKD (eGFR<60 ml/min per 1.73 m2; albumin-to-creatinine ratio ≥30 mg/g, or both) was 25% versus 5.3%, respectively; albumin-to-creatinine ratio ≥30 mg/g was 16% versus 3.0%, respectively; albumin-to-creatinine ratio ≥300 mg/g was 4.6% versus 0.3%, respectively; eGFR<60 ml/min per 1.73 m2 was 12% versus 2.5%, respectively; and eGFR<30 ml/min per 1.73 m2 was 2.4% versus 0.4%, respectively (each P<0.001). Adjusting for demographics and several aspects of BP, prevalence differences were 14.6% (P<0.001), 10.8% (P<0.001), 4.5% (P<0.001), 6.5% (P<0.001), and 1.8% (P=0.004), respectively. Approximately 24% (95% confidence interval, 19% to 29%) of CKD among all United States adults was attributable to diabetes after adjusting for demographics. CONCLUSIONS: Diabetes is strongly associated with both albuminuria and reduced GFR independent of demographics and hypertension, contributing substantially to the burden of CKD in the United States.
BACKGROUND AND OBJECTIVES:Diabetes is an important cause of CKD. However, among people with diabetes, it is unclear to what extent CKD is attributable to diabetes itself versus comorbid conditions, such as advanced age and hypertension. We examined associations of diabetes with clinical manifestations of CKD independent of age and BP and the extent to which diabetes contributes to the overall prevalence of CKD in the United States. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a cross-sectional study of 15,675 participants in the National Health and Nutrition Examination Surveys from 2009 to 2014. Diabetes was defined by use of glucose-lowering medications or hemoglobin A1c ≥6.5%. eGFR was calculated using the CKD Epidemiology Collaboration formula, and albumin-to-creatinine ratio was measured in single-void urine samples. We calculated the prevalence of CKD manifestations by diabetes status as well as prevalence ratios, differences in prevalence, and prevalence attributable to diabetes using binomial and linear regression, incorporating data from repeat eGFR and urine albumin-to-creatinine ratio measurements to estimate persistent disease. RESULTS: For participants with diabetes (n=2279) versus those without diabetes (n=13,396), the estimated prevalence of any CKD (eGFR<60 ml/min per 1.73 m2; albumin-to-creatinine ratio ≥30 mg/g, or both) was 25% versus 5.3%, respectively; albumin-to-creatinine ratio ≥30 mg/g was 16% versus 3.0%, respectively; albumin-to-creatinine ratio ≥300 mg/g was 4.6% versus 0.3%, respectively; eGFR<60 ml/min per 1.73 m2 was 12% versus 2.5%, respectively; and eGFR<30 ml/min per 1.73 m2 was 2.4% versus 0.4%, respectively (each P<0.001). Adjusting for demographics and several aspects of BP, prevalence differences were 14.6% (P<0.001), 10.8% (P<0.001), 4.5% (P<0.001), 6.5% (P<0.001), and 1.8% (P=0.004), respectively. Approximately 24% (95% confidence interval, 19% to 29%) of CKD among all United States adults was attributable to diabetes after adjusting for demographics. CONCLUSIONS:Diabetes is strongly associated with both albuminuria and reduced GFR independent of demographics and hypertension, contributing substantially to the burden of CKD in the United States.
Authors: H H Parving; M A Gall; P Skøtt; H E Jørgensen; H Løkkegaard; F Jørgensen; B Nielsen; S Larsen Journal: Kidney Int Date: 1992-04 Impact factor: 10.612
Authors: Maryam Afkarian; Michael C Sachs; Bryan Kestenbaum; Irl B Hirsch; Katherine R Tuttle; Jonathan Himmelfarb; Ian H de Boer Journal: J Am Soc Nephrol Date: 2013-01-29 Impact factor: 10.121
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Jung-Im Shin; Yingying Sang; Alex R Chang; Stephan C Dunning; Josef Coresh; Lesley A Inker; Elizabeth Selvin; Shoshana H Ballew; Morgan E Grams Journal: J Am Soc Nephrol Date: 2020-07-13 Impact factor: 10.121
Authors: Asher Y Rosinger; Herman Pontzer; David A Raichlen; Brian M Wood; Susan N Tanner; Jeff M Sands Journal: Am J Phys Anthropol Date: 2019-01-31 Impact factor: 2.868
Authors: Ian H de Boer; Leila R Zelnick; Julie Lin; Debra Schaumberg; Lu Wang; John Ruzinski; Georgina Friedenberg; Julie Duszlak; Vadim Y Bubes; Andrew N Hoofnagle; Ravi Thadhani; Robert J Glynn; Julie E Buring; Howard D Sesso; JoAnn E Manson Journal: Contemp Clin Trials Date: 2018-09-30 Impact factor: 2.226
Authors: Lauren J Tanz; Jennifer J Stuart; Paige L Williams; Stacey A Missmer; Eric B Rimm; Tamarra M James-Todd; Janet W Rich-Edwards Journal: J Womens Health (Larchmt) Date: 2018-09-15 Impact factor: 2.681
Authors: Ian H de Boer; Leila R Zelnick; John Ruzinski; Georgina Friedenberg; Julie Duszlak; Vadim Y Bubes; Andrew N Hoofnagle; Ravi Thadhani; Robert J Glynn; Julie E Buring; Howard D Sesso; JoAnn E Manson Journal: JAMA Date: 2019-11-19 Impact factor: 56.272